Sign in
Enrolling by invitationNo phase

Screening adults for MGUS and studying genetic and immune factors

Screens adults aged 40 and older for an abnormal blood protein called MGUS.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
Status
Enrolling by invitation
People taking part
1,000 people, planned
Started
22 May 2024
Expected to end
31 May 2029
Type of study
Observational
Treatments tested
  • Non-Interventional Study
Record updated
11 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older to be screened for MGUS, a condition where an abnormal immune protein is found in the blood. It also studies genetic and immune factors linked to MGUS.

Age
40 years or older
Sex
All sexes can join.

Main reasons for not taking part

  • Pregnant women

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Adults ≥ 40 years
  • Willing and able to review, understand, and provide consent before starting any study-specific procedures
  • Ability to complete questionnaire(s) by themselves or with assistance

Who cannot take part

  • Pregnant women

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.

The group in the trial

  • Observational

    Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.

    Treatment: Non-Interventional Study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study
Plain-language title
Screening adults for MGUS and studying genetic and immune factorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 August 2026